Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers


1. Fx 1006a
2. Fx-1006a
3. Fx1006a
4. Tafamidis
5. Vyndamax
6. Vyndaqel
1. Vyndaqel
2. 951395-08-7
3. Fx-1006a
4. Fx1006a
5. Fx 1006a
6. Zu7cf08a1a
7. Chebi:79345
8. 951395-08-7 (meglumine)
9. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylate
10. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic Acid
11. Unii-zu7cf08a1a
12. Tafamidis Meglumine [usan]
13. Tafamidis Meglumine [usan:inn]
14. Vyndaqel (tn)
15. Chembl2105675
16. Schembl14783506
17. Tafamidis Meglumine [mi]
18. Tafamidis Meglumine (jan/usan)
19. Dtxsid50915094
20. Tafamidis Meglumine [jan]
21. Ex-a3550
22. Hy-14852a
23. Mfcd28502032
24. Tafamidis Meglumine [who-dd]
25. Akos037649321
26. At18247
27. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
28. Tafamidis Meglumine [orange Book]
29. Bs-18043
30. Cs-0045567
31. Pf-06291826
32. D09674
33. Q27148396
34. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylate
35. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)
36. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid--1-deoxy-1-(methylamino)hexitol (1/1)
37. 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic Acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol
38. D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)
39. D-gluco-2,3,4,5,6-pentahydroxy-n-methylhexan-1-aminium 2-(3,5-dichlorophenyl)benzoxazole-6-carboxylate
| Molecular Weight | 503.3 g/mol |
|---|---|
| Molecular Formula | C21H24Cl2N2O8 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 8 |
| Exact Mass | 502.0909711 g/mol |
| Monoisotopic Mass | 502.0909711 g/mol |
| Topological Polar Surface Area | 177 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 506 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Investigated for use/treatment in amyloidosis.
Neuropathic heredofamilial amyloidosis
Fx-1006A is a first-in-class, disease-modifying compound that is designed to inhibit the formation of amyloid deposits by preventing the misfolding and deposition of the transthyretin protein (TTR), which is associated with amyloidosis.
NDC Package Code : 64567-0032
Start Marketing Date : 2025-06-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-09-15
Pay. Date : 2020-08-03
DMF Number : 35066
Submission : 2020-08-05
Status : Active
Type : II
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm :
NDC Package Code : 58159-078
Start Marketing Date : 2020-06-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38912
Submission : 2023-09-26
Status : Active
Type : II
NDC Package Code : 11712-829
Start Marketing Date : 2005-10-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37205
Submission : 2022-06-24
Status : Active
Type : II
NDC Package Code : 73435-024
Start Marketing Date : 2022-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37979
Submission : 2023-02-21
Status : Active
Type : II
Date of Issue : 2025-10-01
Valid Till : 2028-09-30
Written Confirmation Number : WC-0191
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36341
Submission : 2021-11-03
Status : Active
Type : II
Date of Issue : 2025-06-27
Valid Till : 2028-06-16
Written Confirmation Number : WC-0037
Address of the Firm :
NDC Package Code : 58032-2037
Start Marketing Date : 2022-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2020-09-15
Pay. Date : 2020-08-03
DMF Number : 35066
Submission : 2020-08-05
Status : Active
Type : II
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38912
Submission : 2023-09-26
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37205
Submission : 2022-06-24
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37979
Submission : 2023-02-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36341
Submission : 2021-11-03
Status : Active
Type : II
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38304
Submission : 2023-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37026
Submission : 2022-03-31
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-10-04
Pay. Date : 2022-09-07
DMF Number : 37492
Submission : 2022-09-07
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37152
Submission : 2022-06-03
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34696
Submission : 2020-03-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm : Plot No. 111, SIDCO Industrial Estate, Kakkalur, Thiruvallur 602 003, Tamil Nadu...
Date of Issue : 2025-10-01
Valid Till : 2028-09-30
Written Confirmation Number : WC-0191
Address of the Firm : Sy. No. 10, Gaddapotharam (V), Jinnaram (M), Sangareddy District 502319, Telanga...
Date of Issue : 2025-06-27
Valid Till : 2028-06-16
Written Confirmation Number : WC-0037
Address of the Firm : Unit-ll, Plot No. 92-94, 257-259, IDA Pashamylaram, Pashamylaram Village, Patanc...
Date of Issue : 2025-07-07
Valid Till : 2028-07-14
Written Confirmation Number : WC-0021
Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 64567-0032
Start Marketing Date : 2025-06-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-078
Start Marketing Date : 2020-06-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11712-829
Start Marketing Date : 2005-10-04
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
NDC Package Code : 73435-024
Start Marketing Date : 2022-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 58032-2037
Start Marketing Date : 2022-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
NDC Package Code : 69037-0065
Start Marketing Date : 2019-05-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66039-959
Start Marketing Date : 2022-02-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 76339-195
Start Marketing Date : 2024-12-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (0.999kg/.999kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59651-709
Start Marketing Date : 2023-12-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 14501-0101
Start Marketing Date : 2020-03-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Nuray Chemicals Pvt Ltd, established in 2012 near Chennai, is an API manufacturer for highly regulated markets. Its state-of-the-art R&D facility specializes in synthesizing NCEs, ...
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
About the Company : Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingr...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylaram produce high-qual...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
About the Company : Neuland Laboratories, established in 1984 and headquartered in Hyderabad, is a publicly listed company offering solutions for pharmaceutical chemistry needs—from library compound...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Amyloid Neuropathies, Familial.
Lead Product(s): Tafamidis Meglumine,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis Meglumine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Amyloid Neuropathies, Familial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tafamidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Tafamidis,Tafamidis Meglumine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis,Tafamidis Meglumine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tafamidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Analysis from the Phase 3 ATTR-ACT trial for VYNDAQEL (tafamidis meglumine) / VYNDAMAX® (tafamidis), oral transthyretin stabilizers showed a clinically significant 41% reduction in the risk of Heart Failure.
Lead Product(s): Tafamidis Meglumine,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vyndamax
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis Meglumine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients wit...
Details : Analysis from the Phase 3 ATTR-ACT trial for VYNDAQEL (tafamidis meglumine) / VYNDAMAX® (tafamidis), oral transthyretin stabilizers showed a clinically significant 41% reduction in the risk of Heart Failure.
Product Name : Vyndamax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Amyloid Neuropathies, Familial.
Lead Product(s): Tafamidis Meglumine,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis Meglumine,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
Details : Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Amyloid Neuropathies, Familial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
VYNDAQEL® (tafamidis meglumine) 80 mg/VYNDAMAX® (tafamidis) 61 mg were associated with a statistically significant improvement in long-term survival in patients with transthyretin amyloid cardiomyopathy.
Lead Product(s): Tafamidis Meglumine,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vyndamax
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 12, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis Meglumine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Analysis from Phase 3 ATTR-ACT and its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYN...
Details : VYNDAQEL® (tafamidis meglumine) 80 mg/VYNDAMAX® (tafamidis) 61 mg were associated with a statistically significant improvement in long-term survival in patients with transthyretin amyloid cardiomyopathy.
Product Name : Vyndamax
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 12, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tafamidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Tafamidis,Tafamidis Meglumine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis,Tafamidis Meglumine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Determine the Bioequivalence of Two Doses of Tafamidis
Details : Tafamidis is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Tafamidis Meglumine,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tafamidis Meglumine,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects
Details : Tafamidis meglumine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2011

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]methyl 4-(3,5-dichlorobenzamido)-3-hydroxybenzoate
CAS Number : 1184581-58-5
End Use API : Tafamidis Meglumine
About The Company : Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylar...
2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic...
CAS Number : 594839-88-0
End Use API : Tafamidis Meglumine
About The Company : Virupaksha Organics, founded in 2003, is a leading manufacturer of APIs and intermediates. Its FDA-audited, ISO-certified facilities in Kazipally and Pashamylar...
CAS Number : 619-14-7
End Use API : Tafamidis Meglumine
About The Company : Chemvisai Labs is a dynamic pharmaceutical partner established with a clear vision: to become a leading and trusted force in the industry. We address critical u...

4-Amino-3-Hydroxy benzoic acid
CAS Number : 2374-03-0
End Use API : Tafamidis Meglumine
About The Company : Chemvisai Labs is a dynamic pharmaceutical partner established with a clear vision: to become a leading and trusted force in the industry. We address critical u...

4-amino-3-Hydroxy benzoic acid
CAS Number : 2374-03-0
End Use API : Tafamidis Meglumine
About The Company : Synaptics Labs Private Limited is a young Pharmaceutical Company with a fully integrated and globally specialized in the development, production and marketing o...

CAS Number : 2905-62-6
End Use API : Tafamidis Meglumine
About The Company : Synaptics Labs Private Limited is a young Pharmaceutical Company with a fully integrated and globally specialized in the development, production and marketing o...

CAS Number : 51-36-5
End Use API : Tafamidis Meglumine
About The Company : Synaptics Labs Private Limited is a young Pharmaceutical Company with a fully integrated and globally specialized in the development, production and marketing o...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 20MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : VYNDAQEL
Dosage Form : CAPSULE;ORAL
Dosage Strength : 20MG
Packaging :
Approval Date : 2019-05-03
Application Number : 211996
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : U.S.A
Brand Name : Vyndaqel
Dosage Form : Tafamidis 20Mg 30 Joined' Oral Use
Dosage Strength : 30 cps 20 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Vyndaqel
Dosage Form : Soft Capsule
Dosage Strength : 20MG
Packaging :
Approval Date : 2011-11-30
Application Number : 11717001
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Vyndaqel
Dosage Form : Soft Capsule
Dosage Strength : 20MG
Packaging :
Approval Date : 2020-11-03
Application Number : 11717001IP
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : VYNDAQEL
Dosage Form : CAPSULE
Dosage Strength : 20MG
Packaging : 120
Approval Date :
Application Number : 2495732
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
74
PharmaCompass offers a list of Tafamidis Meglumine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tafamidis Meglumine manufacturer or Tafamidis Meglumine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tafamidis Meglumine manufacturer or Tafamidis Meglumine supplier.
PharmaCompass also assists you with knowing the Tafamidis Meglumine API Price utilized in the formulation of products. Tafamidis Meglumine API Price is not always fixed or binding as the Tafamidis Meglumine Price is obtained through a variety of data sources. The Tafamidis Meglumine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tafamidis Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tafamidis Meglumine, including repackagers and relabelers. The FDA regulates Tafamidis Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tafamidis Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tafamidis Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tafamidis Meglumine supplier is an individual or a company that provides Tafamidis Meglumine active pharmaceutical ingredient (API) or Tafamidis Meglumine finished formulations upon request. The Tafamidis Meglumine suppliers may include Tafamidis Meglumine API manufacturers, exporters, distributors and traders.
click here to find a list of Tafamidis Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tafamidis Meglumine DMF (Drug Master File) is a document detailing the whole manufacturing process of Tafamidis Meglumine active pharmaceutical ingredient (API) in detail. Different forms of Tafamidis Meglumine DMFs exist exist since differing nations have different regulations, such as Tafamidis Meglumine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tafamidis Meglumine DMF submitted to regulatory agencies in the US is known as a USDMF. Tafamidis Meglumine USDMF includes data on Tafamidis Meglumine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tafamidis Meglumine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tafamidis Meglumine suppliers with USDMF on PharmaCompass.
A Tafamidis Meglumine written confirmation (Tafamidis Meglumine WC) is an official document issued by a regulatory agency to a Tafamidis Meglumine manufacturer, verifying that the manufacturing facility of a Tafamidis Meglumine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tafamidis Meglumine APIs or Tafamidis Meglumine finished pharmaceutical products to another nation, regulatory agencies frequently require a Tafamidis Meglumine WC (written confirmation) as part of the regulatory process.
click here to find a list of Tafamidis Meglumine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tafamidis Meglumine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tafamidis Meglumine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tafamidis Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tafamidis Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tafamidis Meglumine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tafamidis Meglumine suppliers with NDC on PharmaCompass.
Tafamidis Meglumine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tafamidis Meglumine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tafamidis Meglumine GMP manufacturer or Tafamidis Meglumine GMP API supplier for your needs.
A Tafamidis Meglumine CoA (Certificate of Analysis) is a formal document that attests to Tafamidis Meglumine's compliance with Tafamidis Meglumine specifications and serves as a tool for batch-level quality control.
Tafamidis Meglumine CoA mostly includes findings from lab analyses of a specific batch. For each Tafamidis Meglumine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tafamidis Meglumine may be tested according to a variety of international standards, such as European Pharmacopoeia (Tafamidis Meglumine EP), Tafamidis Meglumine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tafamidis Meglumine USP).